Dr. Glenn Meyer has over 32 years of professional experience and founded Live Oak Pharmaceuticals, Inc. in 2012, providing development services, product profile development, and support for pharmaceutical product development across all dosage forms, routes of administration and appropriate medical devices.
Dr. Meyer started his career at Abbott Laboratories in 1989 after having completed his B.S in Pharmacy at Albany College of Pharmacy and his Ph.D. in Pharmaceutical Chemistry at the University of Connecticut. He participated in a pharmaceutical professional development program learning all aspects of pharmaceutical development. In 1995, Dr. Meyer moved to the CDMO space with Applied Analytica, Inc. (AAI), a laboratory institution, in a managerial role. He served in multiple position ending with responsibility for all internal sponsored research and serving on the Management Teams for a joint venture with Tanabe-Seiyaku and a Collaborative License Agreement with Osmotica Pharmaceuticals. At the end of 2001, Dr. Meyer left AAI to become the US founding employee as Chief Operating Officer at Osmotica Pharmaceuticals, Inc. Three years later, he became the Chief Scientific Officer working to development a pipeline of neuroscience candidates treating muscle spasticity, depression, and Parkinson’s Disease. During his 10 years at Osmotica, Dr. Meyer grew the company from inception to >$100M annually in revenue and from the starting employee to over 250 employees.
Dr. Meyer started his own venture in 2012 assisting companies in developing the products best fitting the profile required and serving the industry in making an optimal dosage form meeting the clinical endpoint, stability, bioavailability, and product performance characteristics desired.
Dr. Meyer has over 25 patents issued to date and numerous publications and continues to expand the boundaries of scientific knowledge through his product development efforts.